Trial Profile
A multi-center, prospective, randomized, double-blind, placebo-controlled, two-arm, phase IV study to investigate the influence of a continuous combined estrogen-progestin regimen containing 2 mg estradiol valerate and 2 mg dienogest (Climodien/Lafamme) on the fat distribution in otherwise healthy early postmenopausal women
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Estradiol valerate/dienogest (Primary)
- Indications Menopausal syndrome
- Focus Pharmacodynamics
- Sponsors Bayer
- 05 May 2009 Actual end date (1 Aug 2004) added as reported by ClinicalTrials.gov
- 05 May 2009 Actual number of patients (70) added as reported by ClinicalTrials.gov
- 21 Jul 2006 New trial record.